Spyre Therapeutics

Historical price data

Spyre Therapeutics is a clinical-stage biotech focused on redefining treatment for inflammatory bowel disease (IBD) and rheumatological conditions by engineering monoclonal antibodies with dramatically extended half-lives. The company's core strategy is to reduce the burden of frequent dosing, aiming for quarterly or twice-annual administration, while targeting validated pathways like α4β7, TL1A, and IL-23. With a multi-asset pipeline centered on the Phase 2 SKYLINE-UC trial and key data readouts expected throughout 2026, Spyre is positioning itself as a potential leader in next-generation, high-convenience biologic therapies.

Proprietary antibody engineering platform focused on extending half-life to enable quarterly or twice-annual dosing and enabling high-concentration co-formulations for subcutaneous combination therapies.